Head-to-head evidence
Elsulfavirine vs Etravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Elsulfavirine · Elpida
Marketed by Viriom
NCT02489461 · Phase 2/3 · completed
The study randomized 150 participants and used double blinding with an active efavirenz comparator. Its primary endpoint was the proportion with HIV-1 RNA below 400 copies/mL at Week 12, but no results are posted, so the outcome comparison cannot be assessed.
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elsulfavirine's landscape · Etravirine's landscape